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Background: More aggressive management of cystic fibrosis (CF), along with the use of new therapies, has led to increasing survival. Thus, the
recommended daily treatment regimens for most CF adults are complex and time consuming.
Methods: In the Project on Adult Care in CF (PAC-CF), an ongoing longitudinal study of CF adults, we assessed self-reported daily treatment
activities and perceived treatment burden as measured by the CF Questionnaire-Revised (CFQ-R), a disease-specific quality of life measure.
Results: Among the 204 respondents, the median number of daily therapies reported was 7 (IQR 5–9) and the mean reported time spent on
treatment activities was 108 minutes per day (SD 58 min). Respondents reported a median of 3 inhaled and 3 oral therapies on the day prior to the
survey. Only 49% reported performing airway clearance (ACT) on that day. There were no differences in the number of medications or the time to
complete therapies based on gender, age or FEV1. The mean CFQ-R treatment burden domain score was 52.3 (SD 22.1), with no significant
differences in the treatment burden based on age or FEV1. In a multivariable model controlling for age, gender, and FEV1, using 2 or more
nebulized medications and performing ACT for ≥30 min were significantly associated with increased treatment burden.
Conclusion: The level of daily treatment activity is high for CF adults regardless of age or disease severity. Increasing number of nebulized
therapies and increased ACT time, but not gender, age, or pulmonary function, are associated with higher perceived treatment burden. Efforts to
assess the effects of high treatment burden on outcomes such as quality of life are warranted.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Treatment burden; Quality of life1. Introduction
The survival of patients with cystic fibrosis (CF) continues to
increase, leading to a growing population of adults living with
CF as a chronic illness. In 2005, over 40% of the US CF patient
population was over the age of 18, and the median predicted
survival for patients with CF has now reached over 36 years [1].
The dramatic increase in longevity in CF occurred not because of
the development of a single therapy, but rather due to the de-
velopment, widespread adoption and maintenance of a clinical⁎ Corresponding author: Children's Hospital Boston, Division of Respiratory
Diseases, 300 Longwood Avenue, Boston, MA 02115, USA. Tel.: +1 617 355
6105; fax: +1 617 730 0097.
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doi:10.1016/j.jcf.2008.09.007care structure which supports patients in complex regimen of
preventions and treatment. For most adult patients, CF care
requires, at a minimum, the daily intake of pancreatic replace-
ment enzymes, nutritional monitoring, airway clearance, inhaled
and nebulized medications, oral anti-inflammatory medications,
and quarterly visits to a specialist clinic [2,3].
Treatment advances in CF require increasing time and effort
and pose continuous challenges to patient self-management
strategies, particularly in adults trying to balance family, work,
education, and other responsibilities with management of chro-
nic disease [4]. Studies of treatment adherence in adults with
CF suggest that levels of adherence to treatment regimes are
similar to those in other chronic illnesses, though they vary by the
type of treatment. Adherence to antibiotic treatment is highest
(80–95%), nebulized medications and pancreatic enzymes isd by Elsevier B.V. All rights reserved.
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cise, and physiotherapy is lowest (40–55%) [5]. These levels
of adherence suggest that adults with CF make daily decisions
about which of the complex array of prescribed therapies they
can complete while fulfilling their responsibilities and commit-
ments to family and work. In an era of an increasing number of
additive therapies in CF, understanding what therapies adults
actually complete and what factors influence their choice of
therapies on a daily basis has become increasingly important.
Such understanding would provide the foundation for improve-
ments in treatments, health outcomes, and quality of life of adults
with CF as well as guide the development of interventions to
support and enhance adherence [5].
One factor that may influence treatment choices is perceived
treatment burden. As the number of therapies increase, there
may be a point at which perceived treatment burden outweighs
the benefits of new or additive therapies, adversely affecting
patient adherence. As a result, perceived treatment burden has
been incorporated into CF-specific HRQOL scales and is mea-
sured as an important outcome in clinical trials [6]. For instance,
in a large trial of nebulized hypertonic saline therapy, many
aspects of HRQOL in CF did improve, yet perceived treatment
burden was increased [7]. Shortening treatment time or im-
proving drug delivery systems has also become a goal in the
development of newer CF therapies, particularly inhaled anti-
biotics, with the intention of decreasing perceived treatment
burden [8]. Substantial treatment burden has been demonstrated
in children with CF, whose caregivers in one study reported
spending 74 minutes per day on treatment tasks [9]. However,
similar data for adults with CF has not been reported, and is
likely to be higher given the natural progression of disease.
As a first step towards understanding decision-making about
CF treatments, we assessed both treatment activities and per-
ceived treatment burden among the cohort of adults with CF
participating in the Project on Adult Care in CF (PAC-CF), an
ongoing longitudinal study of quality of life in adults with CF.
Our specific aims were to describe the daily treatment activities
of CF adults and to examine the relationship between treatment
activities and perceived treatment burden after controlling for
disease severity in this population.
2. Methods
2.1. Study participants
The Project on Adult Care in Cystic Fibrosis (PAC-CF) is
an ongoing prospective, longitudinal panel study of adults
with CF. Adults 18 years of age or older receiving care at one of
ten participating CF Centers were eligible for the study. The
study design and recruitment for PAC-CF has been previously
described [10]. Prior to enrollment, de-identified data from each
center was used to calculate each individual's predicted pro-
bability of surviving 5 years, using Liou's rigorously developed
prognostic model [11]. All adults with a predicted probability of
5-year survival less than 0.975 and a randomly selected 25% of
adults with a predicted probability of 0.975 or higher were
recruited for the study beginning in Fall 2004. This stratifiedsampling design was adopted because adults with a very high
predicted probability of survival were least informative with
respect to the overall PAC-CF goal of examining trends over
time in quality of life as CF progresses. The results in this report
come from the 6th survey wave of PAC-CF, administered to 294
participants in October 2006. The study protocol was approved
by the Institutional Review Boards at Educational Development
Center, Inc. and the ten hospitals in which the participating CF
Centers are located.
2.2. Measures
Treatment activities were assessed through a series of survey
questions in which we asked respondents to report the medi-
cations and therapies that they took on the day prior to the survey.
In contrast to other self-report surveys which focus on self as-
sessment of the degree of adherence to the regimen, we took an
approach based on self management principles in asking adults to
report which treatment activities they had engaged in yesterday,
whether the activities were at a level more than or less than their
usual activity, and why there had been a difference from their
usual pattern. In addition to asking how many times during the
day the treatment was taken or performed, we also included
response options such as “the treatment is prescribed, and I
usually do it, but I did not do it yesterday” and “the treatment is
prescribed but I never do it.” We specifically prompted about 18
common CF medications (nebulized, oral, inhaled via a metered-
dose inhaler (MDI), and other) and 6 common airway clearance
techniques. In contrast to a self-report question on adherence in
general, our questions allowed for responses that indicated that a
respondent had made a decision about a therapy on a particular
day as part of their overall disease self-management strategy.
Treatment burden was assessed using the treatment burden
subscale of the adolescent and adult version of the Cystic Fib-
rosis Questionnaire (CFQ-R), a CF-specific measure of HRQOL
[12]. The treatment burden subscale, which is comprised of 3
questions, is scored on a standardized 0- to 100-point scale on
which lower scores represent higher treatment burden. The
questions on the treatment burden scale in CFQ-R are the fol-
lowing: to what extent do your treatments make your daily life
more difficult?, howmuch time do you currently spend each day
on your treatments?, and how difficult is it for you to do your
treatments each day?
2.3. Statistical analysis
All analyses were performed with SAS software version 9.1
(SAS Institute, Cary, NC). Descriptive statistics, calculated
using sample selection weights (the inverse of the probability of
selection) to adjust for the disproportionate stratified sampling
design, were used to summarize the demographic and clinical
characteristics of the sample and to describe the prevalence and
characteristics of treatment activities and treatment burden.
Subgroup differences by respondent age, gender, and FEV1
were assessed using weighted t-tests or ANOVA, as appropriate.
Respondents were divided into four age groups: 18–24, 25–34,
35–44, and 45+ and three groups based on their best FEV1
Table 2














Airway clearance 29 27
Exercise 29 23
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greater. Differences in CFQ-R treatment burden domain scores
by level of treatment activities were assessed using t-test or
ANOVA. Multivariable linear regression was used to examine
the association of treatment activities with the CFQ-R treatment
burden score, after controlling for age, gender, and pulmonary
function. Four types of treatment activities (nebulized medica-
tion, inhaled medication, oral medication, and airway clearance)
were dichotomized into high and low levels of activity and
included as predictors in the model. Stepwise procedures were
used to identify independent predictors and the final multi-
variate model excluded nonsignificant predictors.
3. Results
3.1. Treatment activities reported by CF adults
The treatment activity survey was completed by 204/294
PAC-CF participants (response rate 69%). The demographics
and clinical characteristics of the respondents are shown in
Table 1. Respondents reported taking many different types of
medications on the day prior to the survey (Table 2). The me-
dian number of total medications reported was 7 (range 0–20).
Respondents reported using the largest number of oral medi-
cations (median 3 per day) and nebulized medications (median
2 per day). When asked to approximate the number of minutes
usually spent on CF therapies, respondents indicated a mean of
108 min per day on all therapies, with a mean of 41 min per day
for nebulized therapy, and 29 min per day for airway clearance,
and 29 min per day for exercise (Table 2). The reported time for
treatments and the number of total medications reported did not
differ significantly by patient age, FEV1, or gender.
Medications that were reported as taken on the day prior to
the survey by a large number of respondents included pancreatic
enzymes (85%), a beta-agonist (65%), anti-reflux medication
(50%), DNase (49%), and azithromycin (47%). Fewer respon-
dents reported taking inhaled steroids (36%), oral antibiotics
(35%), nasal steroids (33%), hypertonic saline (30%), anti-
histamines (29%), or inhaled tobramycin (29%). Some respon-
dents reported that they normally take certain medications, but
did not take them on the day prior to the survey. This was most
commonly reported for azithromycin (22%), nasal steroids
(13%), stool softeners (13%), beta-agonists (10%), and oral
antibiotics (10%). Of the 190 respondents (93%) who reported
using at least one inhaled or nebulized therapy, thirty-nine re-
spondents (21%) said they were using more than usual therapy.
The most commonly reported reasons for using more inhaled
therapies than usual were feeling sicker (69%), and having
enough time to complete therapies (22%). Only 18 (9%) saidTable 1
PAC-CF respondent demographics
Number of respondents (n) 204
Female (%) 62%
Age (years) (mean±SD) 35.4±10
FEV1 (% predicted) (mean±SD) 61±20
Pancreatic sufficient (%) 15%they were using less than usual therapy. The most common
reasons reported for using less than usual therapywere forgetting
(29%), being too busy (29%), preparing for another event (24%),
and feeling healthier than usual (18%). Running out of a
medication was only cited by a small minority (7%) of these
respondents.
One hundred thirty-nine respondents (68%) reported per-
forming at least one airway clearance technique (ACT). The
most commonly reported ACT was the Vest (37% of all re-
spondents), followed by autogenic drainage (25%), manual
chest physical therapy (19%), and a flutter device (15%). Twenty
percent of respondents reported that they normally use a flutter
device, but did not use it the day prior to the survey. A similar
response was given by 13% for the Vest and 13% for manual
chest physical therapy. Seventeen percent of the respondents
reported that they do not use a flutter device even though it is
prescribed, and similar responses were seen for the Vest (11%)
and manual chest physical therapy (9%). With regards to exer-
cise, the majority of respondents (87%) reporting walking, with
29% reporting organized sports activities, 27% bicycling, 25%
using weight training, and 20% jogging. Of the 65 respondents
who did not report doing ACT, 42 (64%) reported that this was
the same as usual. Among the 23 respondents who reported
that no ACT during a day was less than usual, the most com-
monly cited reasons were feeling healthier (30%), being too busy
(20%), getting ready for another event (17%), forgetting (10%),
or using exercise as an alternative form of ACT (10%).
3.2. Treatment burden in CF adults is associated with
treatment activity
The mean CFQ-R treatment burden domain score for the
cohort was 52.3 (SD 22.1). Females reported a higher treatment
burden (mean score 49.9 vs. 56.5, p=0.04), but there were no
significant differences in the treatment burden scale scores based
on age or FEV1 (Table 3). Table 3 also shows the differences in
CFQ-R treatment burden domain score based on different
treatment activities reported. Reporting more treatment activities
was uniformly associated with higher treatment burden (i.e. a
Table 3
CFQ-R treatment burden scale scores differ based on treatment activities
n CFQ-R treatment burden scale a
Mean (SD)
Overall 204 52.3 (22.1)
Gender b
Male 77 56.5 (23.0)
Female 127 49.9 (21.3)
Age (years)
18–24 29 55.9 (17.6)
25–34 70 53.4 (21.8)
35–44 66 48.4 (20.7)
N45 38 55.1 (28.5)
FEV1 (% predicted)
b40% 27 48.1 (20.2)
40%–70% 97 51.1 (20.4)
N70% 55 55.2 (24.1)
# nebulized medications b
0 46 64.3 (24.0)
1 48 59.1 (16.0)
2 46 43.9 (20.6)
≥3 64 45.8 (20.7)
Performed ACTb
No 62 62.8 (23.1)
Yes 142 47.4 (20.0)
# inhaled (MDI) medications b
0 38 60.6 (21.9)
1 62 58.4 (20.2)
2 70 47.0 (20.7)
≥3 34 41.1 (21.6)
# MDI times/day b
0 38 60.6 (21.9)
1–2 65 58.0 (20.8)
3–4 64 48.1 (20.2)
≥5 38 39.7 (21.1)
# oral medications b, c
0–1 70 59.7 (24.8)
2–3 96 48.4 (19.3)
≥4 38 46.7 (20.0)
# oral medication times/day b, c
0 28 65.9 (25.1)
1–2 62 53.8 (21.9)
3–4 74 46.6 (17.6)
≥5 41 48.8 (23.2)
a CFQ-R Treatment Burden Scale is from 0–100, with a lower score repre-
senting a higher treatment burden.
b pb0.05.
c For oral medications, pancreatic enzymes were excluded from analysis.
Table 4
Predictors of higher treatment burden: multivariate linear regression results a
Adjusted b
Level of activity Parameter p
≥2 nebulized medications −9.61 0.0024
≥2 inhaled medications NS
≥3 oral medications NS
≥30 min for ACT −12.72 .0001
a Using≥2 inhaled medications and≥3 oral medications were not significant
predictors and were dropped from the model during stepwise selection.
b Adjusted for age, gender, FEV1, adjusted R-squared=0.198.
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taking more types of nebulized, inhaled, and oral medications
were all associatedwith higher treatment burden, as was reporting
more times per day for taking medication and performing any
airway clearance. In a multivariable model controlling for age,
gender, and FEV1, using 2 or more nebulized medications and
performing airway clearance for 30 or more minutes during the
day were the treatment activities that remained significantly
associated with a lower CFQ-R treatment burden score (Table 4).
4. Discussion
In this study of adults with CF cared for at 10 treatment centers
throughout the United States, a high level of daily treatment ac-tivitieswas reported, with almost 2 hours per day being devoted to
the completion of CF therapies. Perceived treatment burden, as
measured by the CFQ-R, was not associated with disease severity
as measured by pulmonary function, but was significantly higher
in adults who reported completing 30 min or more of airway
clearance and using 2 ormore nebulized therapies. At a timewhen
CF survival is increasing and new therapies are emerging, these
results highlight the significant treatment demands already placed
on adults with CF.
Treatment burden, both objective and perceived, in a chronic
disease such as CF is a function of several factors, including the
number of therapies required on a daily basis, the frequency of
such therapies, the complexity of administering therapies, and
the amount of time needed to complete a therapy. Perceived
treatment burden also depends on how an individual views their
treatment regimen within the context of their other daily de-
mands and responsibilities such as family and work. A recent
study showed that treatment burden is high in children with CF
[9], thus it is no surprise that we found a similarly high treat-
ment burden in CF adults. Interestingly, we found no significant
differences in the number of reported therapies or overall
treatment burden based on age or FEV1, confirming that high
treatment burden in CF begins in late childhood, continues into
adulthood, and is independent of disease severity. The obser-
vation that standard markers of disease severity such as FEV1
are not associated with an individual's perceived treatment
burden is not surprising since most maintenance CF therapies
are initiated prior to adulthood, and often prior to disease pro-
gression. As such, the persistence of high treatment demands in
adult CF care reflects the goals of CF chronic therapies, which
in the absence of curative therapy, are designed to slow disease
progression and extend survival.
A key finding in our analysis is that treatment activities,
particularly the number of nebulized therapies and the time
spent on airway clearance, and not disease severity, are inde-
pendently associated with a higher treatment burden. This un-
derscores the importance of evaluating perceived treatment
burden as an outcome in the development of new CF therapies.
Since many of these therapies are designed to be additive to the
existing treatment regimen, treatment burden may continue to
increase with their use. Indeed, treatment burden was the only
quality of life measure which worsened in the recent ran-
domized trial of hypertonic saline [7]. It is encouraging there-
fore that lowering treatment burden has become one stated goal
95G.S. Sawicki et al. / Journal of Cystic Fibrosis 8 (2009) 91–96in the development of new inhaled antibiotic therapies using
novel delivery devices designed to reduce overall treatment
time [8].
Regular airway clearance has been recommended as a key
component of daily CF therapy. In our survey, the majority of
respondents did report performing some type of ACT or exer-
cise. However, almost one-third of respondents did not report an
ACT activity on the day prior to the survey, and two-thirds of
this group stated that no ACT was usual for them. Thus, ap-
proximately 20% of our respondents report not performing any
regular ACT. This is consistent with other studies of ACT in CF
adults [13], and underscores the need to understand the factors
influencing patient choices with respect to ACT. CF clinicians,
therefore, need to promote ACT adherence in the context of
understanding the treatment burden that ACT imposes.
The CF Foundation recently issued guidelines for pulmonary
maintenance medications based on a rigorous review of clinical
trials, and strongly recommended the daily use of DNase and
inhaled tobramycin, and recommended daily use of hypertonic
saline and regular use of azithromycin [2]. The treatment burden
of following these recommendations is clearly significant. Our
findings on reported daily treatment activities suggest that many
adults may be taking fewer maintenance therapies than are
recommended on a given day. For instance, only one-half of our
cohort reported the use of DNase on the day prior to completing
their survey. Such treatment choices are likely occurring on a
daily basis, perhaps in an effort to reduce treatment burden, and
need to be better understood in the context of patient self-
management. Particularly since perceived treatment burden
may be impacting self-management, future study of challenges
to successful self-management is needed. Such studies, in-
cluding our ongoing work with the PAC-CF cohort, will need to
focus on the relationship between symptom status, treatment
burden, illness perceptions, and competing priorities on the
daily treatment decisions made by adults with CF.
The focus on disease self-management is an important con-
ceptual advance in the understanding of chronic illness and
improving outcomes. Our survey questions signaled an expec-
tation on our part that CF adults are making decision as to which
treatments to do each day, and that there were acceptable reasons
why adults might do so. These reasons need to be incorporated
into a new view of CF disease self-management, one in which
we gain a deeper appreciation of the active role adults can play in
determining their treatment goals and integrating recommended
behaviors into their lives. In fact, in our survey, adults were
willing to admit not completing a recommended treatment. For
example, one quarter of adults said they did not complete any
airway clearance yesterday even though it was recommended.
The main stated reasons for not completing usual therapies
included being too busy and forgetting, both of which have been
cited in prior studies on CF adherence [14]. Importantly, these
reasons suggest that the high treatment burden created by the
multitude of CF maintenance therapies is a major factor in day-
to-day patient decision making.
Our survey has several limitations. We did not examine
medical records so we cannot ascertain what treatment regimens
were prescribed by their clinicians. However, our goal was notto assess adherence to prescribed regimens. We sought to de-
scribe treatment activities as reported by the patient as a step
towards understanding patient-based disease self-management.
Our treatment activity survey was designed to capture the daily
choices that CF adults may make about their therapies rather
than treatment adherence. Although we cannot completely eli-
minate the possibility of over-reporting treatment activity, by
asking respondents to report the therapies that they actually
used on the day prior to the survey, we strove to avoid such
over-reporting by specifically wording the questions to avoid
seeming critical about non-compliance. In addition, this study
did not measure other factors which may influence treatment
activity or perceived treatment burden such as illness percep-
tions and treatment beliefs [15]. Finally, since this is a cross-
sectional survey, we also are unable to comment on how treat-
ment burden changes with disease progression, additions or
changes to therapy over time, or with differences in patient
treatment choices over time. The longitudinal data from the
PAC-CF cohort will allow for such analyses in the future.
In summary, daily treatment activities and perceived treatment
burden are high in all adults with CF regardless of age or disease
severity. Increasing number of nebulized therapies and increased
time spent on airway clearance, but not age or pulmonary
function, is associated with higher perceived treatment burden.
Given the high load of daily therapies, efforts to understand
the determinants of and to lower treatment burden in CF are
warranted. Ultimately, clinicians need the information, skills, and
tools with which to assess both the actual and perceived treatment
burden of their individual patients in order to help those patients
cope with the daily demands of living with CF.
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